Statins are a cornerstone in the medical management of cardiovascular disease, yet their efficacy varies greatly between individuals. In this commentary, we outline the evidence for the role of CD4+CD28null T-cell expansion as a critical moderator of the effects of statins in preventing cardiovascular events via the reduction of pathological inflammation. Given this relationship, we argue that T-cell profiles should be considered as a patient characteristic in clinical and preclinical studies examining statin efficacy in other age- and inflammation-related pathologies. We discuss the implications this may have for studies of statin use in numerous disease processes—notably, dementia and neurocognitive dysfunction—and the potential for T-cell profiles to be used as a prognosticator for statin efficacy in rheumatoid arthritis, Alzheimer’s disease, and multiple sclerosis.

中文翻译：

---

在检查他汀类药物对炎症性疾病、神经退行性和神经认知性能的疗效时考虑 T 细胞谱


他汀类药物是心血管疾病药物治疗的基石，但其疗效因人而异。在本评论中，我们概述了 CD4+CD28 无效 T 细胞扩增作为他汀类药物通过减少病理炎症预防心血管事件的关键调节因子的作用的证据。鉴于这种关系，我们认为在检查他汀类药物在其他年龄和炎症相关病理中的疗效的临床和临床前研究中，应将 T 细胞谱视为患者特征。我们讨论了这可能对他汀类药物在许多疾病过程（特别是痴呆和神经认知功能障碍）中的使用研究产生的影响，以及 T 细胞谱用作类风湿性关节炎、阿尔茨海默病和多发性硬化症中他汀类药物疗效的预测因子的潜力。